Gamma camera probe developer Neoprobe of Dublin, OH, has signed a distribution agreeement with healthcare products firm Cardinal Health, also of Dublin, for the marketing and distribution of its Lymphoseek radiopharmaceutical through Cardinal's network of more than 150 nuclear pharmacies.
The deal grants Cardinal exclusive U.S. rights to distribute the radiopharmaceutical for an initial term of five years once it is cleared by the U.S. Food and Drug Administration (FDA).
Lymphoseek is a lymphatic mapping agent that's labeled with technetium-99m DTPA-mannosyl-dextran, and is designed to be used with handheld gamma detection devices in sentinel lymph node biopsy procedures. The firm reports it is entering phase III clinical trials at this time.
Related Reading
Neoprobe cuts loss on higher sales, October 31, 2007
Cardinal hires Philips executive, August 13, 2007
Neoprobe posts Q2 loss on higher sales, July 26, 2007
Neoprobe signs Cardinal for Lymphoseek sales, July 13, 2007
Neoprobe Lymphoseek trial progresses, June 21, 2007
Copyright © 2007 AuntMinnie.com
